Patent application number | Description | Published |
20090180969 | PHARMACEUTICAL FORMULATION COMPRISING AN ANTICHOLINERGIC DRUG - Pharmaceutical formulations suitable to be administered by pressurised metered dose inhalers (pMDIs) comprising a salt of 3-[[[(3-fluorophenyl)[(3,4,5-trifluoro phenyl)methyl]amino]carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyclo[2.2.2]octane are effective for the prevention and/or treatment of an obstructive airways disease. | 07-16-2009 |
20110146677 | AEROSOL FORMULATION FOR COPD - The stable aerosol solution formulations comprising glycopyrronium chloride are useful for administration to patients with COPD and other respiratory conditions. | 06-23-2011 |
20110150782 | COMBINATION THERAPY FOR COPD - Aerosol formulations comprising glycopyrronium bromide in combination with formoterol are useful for the prevention or treatment of chronic obstructive pulmonary disease. The formulation further comprises a HFA propellant, a co-solvent, and an amount of inorganic acid sufficient to stabilize both the glycopyrronium bromide and the formoterol components. Optionally the formulation may further comprise beclometasone dipropionate. | 06-23-2011 |
20110150783 | AEROSOL FORMULATION FOR COPD - Stable aerosol solution formulations comprising glycopyrronium bromide are useful for administration to patients with COPD and other respiratory conditions. | 06-23-2011 |
20110150784 | COMBINATION THERAPY FOR COPD - Aerosol formulations comprising glycopyrronium chloride in combination with formoterol may be administered by means of a pressurized metered dose inhaler (pMDI) for the prevention or treatment of chronic obstructive pulmonary disease. The formulation further comprises a HFA propellant, a co-solvent, and an amount of inorganic acid sufficient to stabilize both the glycopyrronium chloride and the formoterol components. Optionally, the formulation may further comprise beclometasone dipropionate. | 06-23-2011 |
20120034172 | PHARMACEUTICAL FORMULATION COMPRISING A PHOSPHODIESTERASE INHIBITOR - Pharmaceutical formulations to be administered by pressurized metered dose inhalers (pMDIs), comprising a compound of general formula (I) may be used for the treatment and/or prevention of inflammatory or obstructive airway diseases. | 02-09-2012 |
20140363383 | AEROSOL FORMULATION FOR COPD - The stable aerosol solution formulations comprising glycopyrronium chloride are useful for administration to patients with COPD and other respiratory conditions. | 12-11-2014 |
20140363384 | COMBINATION THERAPY FOR COPD - Aerosol formulations comprising glycopyrronium chloride in combination with formoterol may be administered by means of a pressurized metered dose inhaler (pMDI) for the prevention or treatment of chronic obstructive pulmonary disease. The formulation further comprises a HFA propellant, a co-solvent, and an amount of inorganic acid sufficient to stabilize both the glycopyrronium chloride and the formoterol components. Optionally, the formulation may further comprise beclometasone dipropionate. | 12-11-2014 |